Skip to content
value.today

Monopar Therapeutics

🇺🇸 Lake Forest, Illinois, USABiotechnologyFounded 2014
Total raised
$2 M
1 round on record
Latest round
$2 M
Jun 2015
First round on record
Jun 2015
Today
Went public
See the company page

Monopar Therapeutics is listed today as Monopar Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Monopar Therapeutics
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2015$2 MNo. 1$2 to $10 million

Monopar Therapeutics: Raise no. 1, Jun 2015

Investors in this round

8 investors had bought by the notice of Jun 18, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
$250,020
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,395,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Andrew P. Mazar · Executive Officer, Director
  • Chandler D. Robinson · Executive Officer, Director, Promoter
  • Christopher M. Starr · Executive Officer, Director
  • Michael J. Brown · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Includes compensation, benefits, consulting fees of executive officers and principals, and reimbursement of expenses incurred by the Initial Member.”

Signed by Chandler D. Robinson, Ceo. Source: SEC Form D, newest notice filed Jun 18, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Monopar Therapeutics chose not to state its revenue in its newest notice of a funding round (Jun 2015).

    SEC Form D · Jun 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2015

That is all the official record says: Monopar Therapeutics has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Monopar Therapeutics are on record.

Investors#

No investor of Monopar Therapeutics is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.

Largest shareholders today

Institutions holding Monopar Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Monopar Therapeutics
NameRoleNamed in
Andrew P. MazarExecutive officerJun 2015
Chandler D. RobinsonExecutive officerJun 2015
Christopher M. StarrExecutive officerJun 2015
Andrew P. MazarDirectorJun 2015
Chandler D. RobinsonDirectorJun 2015
Christopher M. StarrDirectorJun 2015
Michael J. BrownDirectorJun 2015
Chandler D. RobinsonPromoterJun 2015

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.